DDInter717 DDInter856
Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients typically display delayed development and neurocognitive impairment.[A214694, A214709, A214712, A214715] Fenfluramine is a serotonergic phenethylamine originally used as an appetite suppressant until concerns regarding cardiotoxicity in obese patients lead to its withdrawal from the market in 1997.[A214694, A214718, A11906] Through its ability to modulate neurotransmission, fenfluramine has reemerged as an effective therapy against pharmacoresistant seizures, such as those involved in Dravet syndrome.[A214688, A214691, A214700] Fenfluramine was granted initial FDA approval in 1973 prior to its withdrawal
Unfractionated heparin (UH) is a heterogenous preparation of anionic, sulfated glycosaminoglycan polymers with weights ranging from 3000 to 30,000 Da. It is a naturally occurring anticoagulant released from mast cells. It binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin (factor IIa) and factor Xa. UH is different from low molecular weight heparin (LMWH) in the following ways: the average molecular weight of LMWH is about 4.5 kDa whereas it is 15 kDa for UH; UH requires continuous infusions; activated partial prothrombin time (aPTT) monitoring is required when using UH; and UH has a higher risk of bleeding and higher risk of osteoporosis in long term use. Unfractionated heparin is more specific than LMWH for thrombin. Furthermore, the effects of UH can typically be reversed by using protamine sulfate.
Fenfluramine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tolterodine
Fenfluramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eliglustat
Fenfluramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eptifibatide
Fenfluramine {u} may lead to a major life threatening interaction when taken with {v} Phendimetrazine
Fenfluramine {u} may lead to a major life threatening interaction when taken with {v} Fluvoxamine
Fenfluramine may cause a minor interaction that can limit clinical effects when taken with Tolterodine
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Eptifibatide
Fenfluramine may lead to a major life threatening interaction when taken with Phendimetrazine
Fenfluramine may lead to a major life threatening interaction when taken with Fluvoxamine